Table 3. Overview of liposomal applications for lung disease treatments.

Application	Formulation	Development stage	Administration	Ref
Mycobacterium avium complex (MAC) lung disease	DPP C :Cholosterol liposomal amikacin, 300 nm	FDA approved	Inhalation	[196–199]
Lung cancer	PEG-modified liposomal Irinotecan, formulated by utilizing sucrose octasulfate gradient, 110 nm	Now in Phase III clinical trial for lung cancer	Intravenous	[205]
	PEG-modified liposomal cisplatin, 110 nm	Phase III clinical trial	Intravenous	[206–208]
	Dual-ligand anti-CA IX antibody and CPP33 liposomal Triptolide (TPL), 137 nm	Pre-clinical	Endotracheal	[209]
Lung inflammation	IgG-modified liposomal dexamethasone, 103 nm	Pre-clinical	Intravenous	[202]
Cystic fibrosis (CF)	PEG-modified liposomal nanoparticle encoding mRNA of CFTR protein	Phase I/II clinical trial	Inhalation	[214]
	Cationic GL67A liposomes with plasmid DNA encoding CFTR protein	Phase I clinical trial	Inhalation	[223,224]
	Epithelial targeted liposome with ENaC siRNA, 200 nm	Pre-clinical	Inhalation	[242]
Neonatal SP-B deficiency	Cationic liposomes with SP- B mRNA	Pre-clinical	Intravenous	[215]
Chronic obstructive pulmonary disease (COPD)	Self-assembling ionizable lipid nanoparticle with mRNA for a1-antitrypsin (AAT)	Pre-clinical	Intravenous	[216,243]
Asthma	Liposomes encapsulating salbutamol sulfate	Pre-clinical	Inhalation	[203,204]